APPLICATIONS

Bound-less Bio-tech

Vaccines

Vaccines Development

Protective immunity to encapsulated bacteria involves development of an antibody response to a polysaccharide (PS) antigen, interactions with T and B lymphocytes, and host defense mechanisms. Polysaccharide vaccines have evolved as a unique class of inactivated subunit vaccine, composed of long chains of sugar molecules that make up the surface capsule of certain bacteria.

As T-cell independent antigens, including polysaccharide vaccines, are not consistently immunogenic in children < 2 years of age, conjugate vaccines have come into use since conjugation changes the immune response from T-cell independent to T-cell dependent, leading to increased immunogenicity in infants and antibody booster response to multiple doses of vaccine.

 

Premas collaborates with partners for development of polysaccharide vaccines and conjugate vaccines, pilot studies, process development for fermentation and purification, large scale production and analytical characterization with our clients and partners.

Two vaccine candidate development programs that we are engaged in have progressed to field trials. Apart from PS development program, Premas has developed multiple vaccine candidates and their critical reagents for human and animal use. We’ve completed over 25 projects associated with such developmental programs.

Premas has completed Bacterial, Viral, Anti-Helminthic, Dental (ScFV based) vaccines and their development. Some of them include RSV epitopes antigens, VLPs, Glyco-proteins (antigenic), receptors, etc. We have served the animal health programs for bovine, porcine, canine, etc vaccine therapeutics. Premas has developed a recombinant carrier protein CRM 197 using the E coli expression platform as a secretory protein. Biophysical and functional characterization demonstrate comparability and bettering of effect with the existing commercially available molecules.

Corona Virus

D-Crypt for Covid 19

Premas specializes in developing recombinant proteins for vaccine development. Such proteins are often “difficult to express proteins” (DTE-Ps). Our innovative D-Crypt platform is optimized for highyield production of DTE-Ps, singularly, or in combination.

Through a partnership with Akers Biosciences, Premas is leveraging DCrypt to develop a multicomponent recombinant protein vaccine against COVID-19.

Contact Us to learn more about our COVID-19 Vaccine Candidate or about our vaccine development services.

Know more